Egyptian hepatitis b study seeks to uncover drug resistance patterns

NCT ID NCT07274345

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will enroll 2,000 Egyptian patients with chronic hepatitis B to find out how common antiviral drug resistance is and what factors make it more likely. Researchers will look at patients taking common antiviral drugs like tenofovir, entecavir, or lamivudine. The goal is to improve treatment choices and long-term care for hepatitis B patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this study could help doctors choose better antiviral treatments for chronic hepatitis B patients in Egypt, reducing the chance of drug resistance.

What could go wrong

This is an observational study, not a treatment trial, so it won't directly improve patient health. The findings may not apply to other populations or regions.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B - ANTIVIRAL DRUG RESISTANCE - HEPATITIS B VIRUS (HBV) INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection hepatitis B virus infection Infections

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••